PODD Stock Recent News

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2023 on February 22, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Insulet (PODD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Investors are optimistic about Insulet (PODD), led by the strong adoption of Omnipod 5 and its strong solvency position.

Here is how to utilize the Filtered Zacks Rank 5 Stock Screen to help find potentially winning stocks to buy to close out December and throughout 2024.

Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.

Invest in stocks such as Insulet (PODD), W.R. Berkley (WRB), Invitation Home (INVH) and VICI Properties (VICI) for superb earnings growth.

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at two upcoming investor conferences (all Eastern Time): The Nasdaq 29th Investor Conference in London on Tuesday, December 5, 2023 at 10:00 a.m. The J.P. Morgan Annual Healthcare Conference in San Francisco on Tuesday, January 9, 2024 at 12:45 p.m. To listen to the live audio webcasts.

Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.

Insulet (PODD) continues to gain from the strong adoption of Ommipod 5 and market expansion.